title: MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma.
abstract: OBJECTIVE
  To compare microRNA (miR) expression between patients with diffuse large B-cell lymphoma (DLBCL) who had a poor prognosis to those who had a favorable prognosis.
  
  
  METHODS
  The study group included 83 patients with diffuse large B-cell lymphoma (DLBCL) treated between the years 1995 and 2003 without rituximab in a single tertiary center for whom adequate tumor content was available. miR signature from tissue biopsies was compared between patients who relapsed within nine months from commencement of treatment (defined as poor prognosis, n=43) and those with disease-free survival of at least five years (defined as good prognosis, n=40). RNA was analyzed using custom microarrays. Quantitative real-time polymerase chain reaction (qRT-PCR) was used for technical validation of microarray results. An independent set of 13 samples was used for further validation.
  
  
  RESULTS
  Eight miRs were found to be differently expressed between the two prognostic groups. The expression of the different miRs was verified by qRT-PCR, showing high correlation with the microarray data in both verification and independent set groups. No added value to the clinically based International Prognostic Index was found.
  
  
  CONCLUSIONS
  miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses.
authors: Medicine A, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: Shepshelovich@yahoo.com.
authors: Daniel
authors: D
authors: Shepshelovich
authors: BMT Unit, Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Ron
authors: R
authors: Ram
authors: Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Orit
authors: O
authors: Uziel
authors: Rosetta Genomics Ltd., Israel.
authors: Michal
authors: M
authors: Kushnir
authors: Rosetta Genomics Ltd., Israel.
authors: Gila
authors: G
authors: Lithwick-Yanai
authors: Rosetta Genomics Ltd., Israel.
authors: Moshe
authors: M
authors: Hoshen
authors: Department of Pathology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Meora
authors: M
authors: Feinmesser
authors: Institute of Hematology, Davidoff Centre, Rabin Medical Centre, Beilinson Hospital, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Osnat
authors: O
authors: Bairey
authors: Medicine A, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Institute of Hematology, Davidoff Centre, Rabin Medical Centre, Beilinson Hospital, Petah Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Meir
authors: M
authors: Lahav
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D018572:Disease-Free Survival; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis*; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
chemical_list: D035683:MicroRNAs; D012334:RNA, Neoplasm
keywords: Lymphoma; MicroRNA; Prognosis